Skip to content

US · STTK · BIOTECHNOLOGY

Shattuck Labs, Inc. (STTK) intrinsic value and stock valuation

$4.46as of 2026-11-21 · Mkt cap 353.05M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Shattuck Labs, Inc. DCF and intrinsic value

InvestorsCraft values STTK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from STTK’s statements →

Shattuck Labs, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Austin, TX 78701 shattucklabs.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$1M-36.8% 5y CAGRd
20182025
Net income
-$-48.81M
20182025
Free cash flow
-$-39.95M
20182025
Total equity
$82.4M-23.3% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$1M$5.72M$1.66M$650K$30M
Operating income-$-51.51M-$-80.57M-$-91.96M-$-103.33M-$-45.27M
Net income-$-48.81M-$-75.41M-$-87.3M-$-101.94M-$-44.97M
EPSd-$-701.49K-$-1.49M-$-2.05M-$-2.41M-$-1.07M
Operating cash flow-$-39.88M-$-60.52M-$-81.23M-$-94.5M-$-57.12M
Capital expenditure-$-70K-$-60K-$-410K-$-11.61M-$-7.93M
Free cash flow-$-39.95M-$-60.57M-$-81.64M-$-106.11M-$-65.04M
Total assets$91M$91.1M$159.6M$205.3M$298.6M
Total debt$2.42M$3.41M$4.2M$4.9M$0.00
Net debt-$-51.77M-$-53.98M-$-121.42M-$-42.48M-$-92.27M
Total equity$82.4M$79.6M$144.7M$176.2M$271.8M
Cash and short-term investments$78.1M$73M$130.6M$161.3M$268.8M
Income statement
20252024202320222021
Revenue$1M$5.72M$1.66M$650K$30M
Cost of revenue$2.95M$4.89M$4.04M$82.2M$1.38M
Gross profit-$-1.95M$830K-$-2.38M-$-81.55M$28.6M
Research and development expenses$35.3M$67.2M$74.3M$82.9M$56.6M
Selling, general and administrative expenses$17.2M$19.1M$19.3M$19.7M$18.7M
Other expenses-$-2.95M-$-4.89M-$-4.04M-$-80.8M-$-1.38M
Operating expenses$49.6M$81.4M$89.6M$21.8M$73.9M
Cost and expenses$52.5M$86.3M$93.6M$104M$75.3M
Interest income$2.7M$5.17M$4.67M$1.59M$620K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$3.69M$3.83M$4.04M$3.07M$1.38M
Ebitda-$-45.12M-$-71.58M-$-83.26M-$-98.87M-$-43.59M
Operating income-$-51.51M-$-80.57M-$-91.96M-$-103.33M-$-45.27M
Total other income/expenses, net$2.7M$5.16M$4.66M$1.38M$290K
Income before tax-$-48.81M-$-75.41M-$-87.3M-$-101.94M-$-44.97M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-48.81M-$-75.41M-$-87.3M-$-101.94M-$-44.97M
Weighted average shares outstanding$69.6M$50.8M$42.6M$42.4M$42M
Weighted average diluted shares outstanding$69.6M$50.8M$42.6M$42.4M$42M
Balance sheet
20252024202320222021
Cash and short-term investments$78.1M$73M$130.6M$161.3M$268.8M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$82.5M$79.2M$143.2M$184.6M$288.3M
Property, plant and equipment, net$6.11M$9.81M$13.8M$17.7M$9.94M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1M$0.00$0.00$0.00$0.00
Total non-current assets$8.55M$11.8M$16.3M$20.7M$10.3M
Total assets$91M$91.1M$159.6M$205.3M$298.6M
Accounts payable$2.1M$2.42M$1.59M$7.17M$10M
Short-term debt$840K$900K$800K$700K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.05M$8.92M$11.5M$25M$24.6M
Long-term debt$1.58M$2.51M$3.41M$4.2M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.58M$2.51M$3.41M$4.2M$2.21M
Capital lease obligations$840K$3.41M$4.2M$4.9M$0.00
Total liabilities$8.64M$11.4M$14.9M$29.2M$26.8M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-430.53M-$-381.72M-$-306.31M-$-219.01M-$-117.07M
Accumulated other comprehensive income (loss)$10K$0.00$0.00-$-880K-$-560K
Total equity$82.4M$79.6M$144.7M$176.2M$271.8M
Total investments$24.9M$15.6M$5M$113.9M$176.5M
Total debt$2.42M$3.41M$4.2M$4.9M$0.00
Net debt-$-51.77M-$-53.98M-$-121.42M-$-42.48M-$-92.27M
Cash flow statement
20252024202320222021
Net income-$-48.81M-$-75.41M-$-87.3M-$-101.94M-$-44.97M
Depreciation and amortization$3.69M$3.83M$4.04M$3.07M$1.38M
Stock-based compensation$7M$9.55M$6.94M$6.46M$5.47M
Change in working capital-$-790K$3.02M-$-4.09M-$-4.46M-$-23.55M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-320K$830K-$-5.63M-$-2.84M$7.87M
Net cash provided by operating activities-$-39.88M-$-60.52M-$-81.23M-$-94.5M-$-57.12M
Investments in property, plant and equipment-$-70K-$-60K-$-410K-$-11.61M-$-7.93M
Acquisitions, net$0.00$0.00$0.00$100K$2.52M
Net cash used for investing activities-$-7.89M-$-8.51M$110.9M$49.4M-$-10.44M
Common stock issued$44.5M-$-20K$48.7M$170K$1.93M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$44.6M$790K$48.6M$170K$1.93M
Net change in cash-$-3.19M-$-68.24M$78.3M-$-44.89M-$-65.63M
Cash at end of period$54.2M$57.4M$125.6M$47.4M$92.3M
Operating cash flow-$-39.88M-$-60.52M-$-81.23M-$-94.5M-$-57.12M
Capital expenditure-$-70K-$-60K-$-410K-$-11.61M-$-7.93M
Free cash flow-$-39.95M-$-60.57M-$-81.64M-$-106.11M-$-65.04M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Shattuck Labs, Inc.

        Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

        CEO
        Taylor H. Schreiber
        Employees
        40
        Beta
        1.06

        Explore

        Frequently asked questions

        What is the intrinsic value of Shattuck Labs, Inc. (STTK)?

        Shattuck Labs, Inc. (STTK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is STTK undervalued?

        STTK trades at a price of $4.46 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.